Matrix metalloproteinase 13 (MMP-13) (MMP-13)

Matrix metalloproteinase 13 (MMP-13), also known as collagenase 3, is a zinc-dependent endopeptidase that plays a pivotal role in the degradation of the extracellular matrix, specifically targeting type II collagen in articular cartilage (UniProt P45452). Its expression is normally low in adult tissues but is significantly upregulated in pathological states like osteoarthritis and various cancers through multiple signaling pathways, including MAPK, Wnt/beta-catenin, and NF-kappaB (PubMed: 27538661). In osteoarthritis, MMP-13 is considered the primary enzyme responsible for irreversible cartilage destruction, making it a high-priority therapeutic target. In oncology, MMP-13 facilitates tumor invasion, angiogenesis, and metastasis by remodeling the basement membrane and releasing growth factors (PubMed: 21455377). Therapeutic strategies include direct small-molecule inhibitors and indirect modulation of the gene expression pathways that drive its production. However, clinical development has been hindered by the need for high selectivity to avoid musculoskeletal syndrome, a side effect associated with broad-spectrum MMP inhibition (PubMed: 23613405).

Other names

Collagenase 3MMP13CLG3Matrix metallopeptidase 13

Small molecule inhibition of the MMP-13 catalytic domain or allosteric sites to prevent collagen degradation; indirect modulation via inhibition of upstream signaling pathways (e.g., MAPK, NF-kappaB) that regulate MMP-13 gene expression.